Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation study of NN1731 (activated recombinant FVII analogue) for treatment of joint bleeds in haemophilia with inhibitors
2006-004879-35Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vatreptacog alfa in hemophilia A, hemophilia B (HB) and hemarthrosis (4 arms), sponsored by Novo Nordisk. Primary endpoints: Safety (adverse events) and Efficacy of NN1731. Started Jan 2007; status: completed.
02
Drugs
vatreptacog alfa
03
Conditions
hemophilia Ahemophilia B (HB)hemarthrosis
Beyond the preview
Go deeper on 2006-004879-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004879-35.